The mechanism that we propose for such chemosensitization – i.e. the inhibition of ABC transporters activity – might help to explain why a dietary supplementation with ω3PUFAs improves the efficacy of irinotecan in mice bearing colon cancer[64], the efficacy of anthracyclines in patients with breast cancer[65], the efficacy of cisplatin plus vinorelbine in patients with non small cell lung cancer[66]. This evidence concerns the gene ABCG2 and breast carcinoma.